Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review

Blood Adv. 2020 Mar 10;4(5):815-818. doi: 10.1182/bloodadvances.2019001215.

Authors

Yazan Migdady¹, Asiri Ediriwickrema², Ryan Patrick Jackson¹, Wendy Kadi¹, Ridhi Gupta³, Francisco Socola⁴, Sally Arai³, Beth A Martin²

Affiliations

¹ Stanford University, Stanford, CA.
² Division of Hematology, Stanford University School of Medicine, Stanford, CA.
³ Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, CA.
⁴ Tulane University Medical Center, New Orleans, LA; and.

Abstract

A source of treatment refractoriness in immune cytopenias appears to be residual CD138/38-positive lymphocyte populations.
A short course of daratumumab is a novel treatment of refractory thrombocytopenia after failure of standard treatment options.

Publication types

Case Reports
Review

MeSH terms

Allografts
Antibodies, Monoclonal* / therapeutic use
Humans
Thrombocytopenia* / drug therapy

Substances

Antibodies, Monoclonal
daratumumab